ArticleNature biomedical engineering2026
Engineering inflammation-responsive proteins through nitric oxide-caged amino acids.
Article in Nature biomedical engineering, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Nitric oxide is upregulated in inflammatory tissues but has not been used to directly control the activity of folded proteins. Here we report a protein engineering strategy that enables selective restoration of protein function in nitric oxide-rich environments. Protein activity is temporarily suppressed by site-specific substitution of a catalytically or structurally essential glutamate residue with a synthetic amino acid whose side chain is chemically masked. Exposure to nitric oxide triggers decaging of this residue, regenerating the native glutamate and restoring protein function. Using this approach, we engineer nitric oxide-responsive variants of antibodies, enzymes, cytokines, bacterial toxins and viral capsids. In mouse models, this strategy enables inflammation-localized protein activation, selective viral gene delivery in inflamed tissues and rapid detection of intestinal inflammation using engineered probiotic biosensors. These results establish nitric oxide-triggered chemical reactivation of proteins as a generalizable method for post-translational control of protein function, with potential applications in inflammation-targeted therapeutics, gene delivery and biosensing.
Identifiers
42675181What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.